<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="69253">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02204267</url>
  </required_header>
  <id_info>
    <org_study_id>MonDAFIS</org_study_id>
    <secondary_id>EA2/033/14</secondary_id>
    <nct_id>NCT02204267</nct_id>
  </id_info>
  <brief_title>Impact of Standardized MONitoring for Detection of Atrial Fibrillation in Ischemic Stroke</brief_title>
  <acronym>MonDAFIS</acronym>
  <official_title>Impact of Standardized MONitoring for Detection of Atrial Fibrillation in Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigator-initiated prospective randomized multicentre study to uncover the true burden
      of paroxysmal atrial fibrillation in a representative population of acute stroke patients
      without known atrial fibrillation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients on oral anticoagulation (NOAC or VKA)</measure>
    <time_frame>12 months</time_frame>
    <description>Number of study patients on oral anticoagulation (NOAC or VKA) at 12 months after the index stroke either randomized to standardized prolonged ECG monitoring in-hospital or those randomized to usual stroke unit diagnostic procedures alone.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of stroke patients with newly detected atrial fibrillation</measure>
    <time_frame>7 days</time_frame>
    <description>Number of stroke patients with newly detected atrial fibrillation using a standardized prolonged ECG monitoring compared to usual stroke unit diagnostic procedures alone.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Impact of stroke unit level on the rate of atrial fibrillation detection</measure>
    <time_frame>7 days</time_frame>
    <description>Impact of stroke unit level (i.e. primary or comprehensive stroke center) on the rate of atrial fibrillation detection in-hospital stroke in patients randomized to standardized prolonged ECG monitoring in hospital</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of recurrent strokes, major bleeds, myocardial infarction and all-cause death (composite endpoint) within 6, 12 and 24 months after the index stroke</measure>
    <time_frame>24 months</time_frame>
    <description>Number of recurrent strokes, major bleeds, myocardial infarction and all-cause death (composite endpoint) within 6, 12 and 24 months after the index stroke in patients either randomized to standardized prolonged ECG monitoring in-hospital or those randomized to usual stroke unit diagnostic procedures alone.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3470</enrollment>
  <condition>Stroke</condition>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>prolonged ECG monitoring</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regular stroke unit treatment and diagnostic procedures according to guidelines and additional prolonged ECG monitoring</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no additional ECG recording</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Regular stroke unit treatment and diagnostic procedures according to guidelines</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>prolonged ECG monitoring</intervention_name>
    <description>Start of long-term ECG immediately after admission to the stroke unit by using a portable ECG recorder for a max. duration of 7 days (or hospital discharge)</description>
    <arm_group_label>prolonged ECG monitoring</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ECG</intervention_name>
    <arm_group_label>prolonged ECG monitoring</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute ischemic stroke or transitory ischemic attack (with clinical deficit on
             enrolment or MRI detected acute brain lesion on admission)

          -  Age ≥ 18 years

          -  Written or oral informed consent

          -  Stroke unit admission within 72 hours after stroke onset

          -  Start of standardized prolonged ECG monitoring within 24 hours after admission to the
             stroke unit

          -  Willingness to take part in the planned follow up examinations

        Exclusion Criteria:

          -  Known atrial fibrillation

          -  Atrial fibrillation detected by ECG on admission

          -  Atrial fibrillation detected prior study enrollment on the stroke unit

          -  Life expectancy &lt; 1 year (before actual stroke)

          -  Life expectancy &lt; 1 month (after actual stroke)

          -  Indication for oral anticoagulation other than atrial fibrillation (e.g. mechanical
             heart valve)

          -  Severity level according National Institute of Health Stroke Scale (NIHSS) score &gt; 22

          -  Participation in an interventional trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Endres, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Stroke Research Berlin, Charité University Berlin, Campus Mitte</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claudia Kunze, BA</last_name>
    <phone>49 30 450560678</phone>
    <email>c.kunze@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karl Georg Häusler, MD, FESC</last_name>
    <phone>49 30 450560663</phone>
    <email>georg.haeusler@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charité Universitaetsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karl G Haeusler, MD; FESC</last_name>
      <phone>0049 30 450 560 663</phone>
      <email>georg.haeusler@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Claudia E Kunze, BA</last_name>
      <phone>0049 30 450 560 678</phone>
      <email>c.kunze@charite.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 8, 2016</lastchanged_date>
  <firstreceived_date>July 29, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Matthias Endres</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>Stroke</keyword>
  <keyword>atrial fibrillation</keyword>
  <keyword>ECG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
